Ekso Bionics Files S-1/A Amendment

TL;DR

EKSO filed an S-1/A. Looks like they're updating their registration. Keep an eye on this.

AI Summary

Ekso Bionics Holdings, Inc. filed an S-1/A amendment on August 28, 2024, to its registration statement. The company, incorporated in Nevada, is involved in the General Industrial Machinery & Equipment sector. Its principal executive offices are located at 101 Glacier Point, Suite A, San Rafael, California.

Why It Matters

This filing indicates ongoing regulatory activity and potential future stock offerings or changes for Ekso Bionics, a company in the industrial machinery sector.

Risk Assessment

Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which can introduce volatility.

Key Numbers

• 333-281081 — SEC File Number (Identifies the specific SEC registration)
• 0001549084 — Central Index Key (Unique identifier for the company in SEC filings)

Key Players & Entities

• EKSO BIONICS HOLDINGS, INC. (company) — Registrant
• August 28, 2024 (date) — Filing Date
• Nevada (jurisdiction) — State of Incorporation
• 101 Glacier Point, Suite A, San Rafael, California 94901 (address) — Principal Executive Offices
• Scott G. Davis (person) — Chief Executive Officer

FAQ

Key Financial Figures

• $0 — ne share of our common stock, par value $0.001, one Series A warrant to purchase o
• $0.001 — rice of each pre-funded warrant will be $0.001 per share of common stock. The pre-fund
• $1.13 — price of our common stock on Nasdaq was $1.13 per share. There is no established trad
• $91,031.93 — CMS") approved a final payment level of $91,031.93 for Medicare reimbursement of the Ekso
• $250 million — on stock held by non-affiliates exceeds $250 million as of the prior June 30 or (ii) our ann
• $100 million — 30 or (ii) our annual revenue exceeded $100 million during such completed fiscal year and t
• $700 million — on stock held by non-affiliates exceeds $700 million as of the prior June 30. Corporate Inf
• $5.3 m — from the offering will be approximately $5.3 million, based on an assumed public offer
• $31.95 — at a weighted average exercise price of $31.95 per share, 1,082,327 restricted stock u
• $8.90 — at a weighted average exercise price of $8.90 per share. Unless expressly indicated
• $1 — fering price of each pre-funded unit of $1.129, are substantially higher than the
• $0.62 — r immediate and substantial dilution of $0.62 per share in the as adjusted net tangib
• $4.1 million — ferings. Through June 30, 2024, we have $4.1 million available for future offerings under th

Filing Documents

• ekso20240828_s1a.htm (S-1/A) — 428KB
• ex_719288.htm (EX-1.1) — 531KB
• ex_719289.htm (EX-4.10) — 108KB
• ex_719290.htm (EX-4.11) — 103KB
• ex_719291.htm (EX-5.1) — 24KB
• ex_719292.htm (EX-5.2) — 12KB
• ex_719293.htm (EX-23.1) — 3KB
• ex_719294.htm (EX-FILING FEES) — 36KB
• logo01.jpg (GRAPHIC) — 7KB
• logo02.jpg (GRAPHIC) — 6KB
• swlogo01.jpg (GRAPHIC) — 8KB
• wslogo01.jpg (GRAPHIC) — 11KB
• 0001437749-24-027894.txt ( ) — 1292KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 9 Market, Industry and Other Data 10

USE OF PROCEEDS

USE OF PROCEEDS 11 DIVIDEND POLICY 12 CAPITALIZATION 13

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 15 CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS 20

UNDERWRITING

UNDERWRITING 27 LEGAL MATTERS 31 EXPERTS 31 WHERE YOU CAN FIND MORE INFORMATION 31 Incorporation of Certain Information by reference 32 Neither we nor the underwriter have authorized anyone to provide any information or to make any representations other than those contained or incorporated by reference in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained or incorporated by reference in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of securities. For investors outside the United States, neither we nor the underwriter have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required. Persons outside the United States who come into possession of this prospectus and any free writing prospectus related to this offering are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. i Table of Contents PROSPECTUS SUMMARY This summary highlights certain information about us and this offering. Because it is a summary, it does not contain all of the information that you should consider before investing. Before investing in our securities, you should read this entire prospectus and the documents incorporated by reference carefully, including the " Risk Factors, " and the financial statements and accompanying notes and other information included and incorporated by reference in th

RISK FACTORS

RISK FACTORS Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described below, and those discussed under the headings " Risk Factors " contained in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and our Annual Report on Form 10-K for the year ended December 31, 2023, which are incorporated by reference into this prospectus, together with the other information contained in this prospectus and the documents incorporated by reference herein. If any of these risks is realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our securities could decline and you could lose part or all of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment. Management will have broad discretion as to the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment. Our management will have broad discretion over the use of proceeds from the sale of shares of our common stock in this offering, including for any of the purposes described in the section of this prospectus entitled "Use of Proceeds," and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to apply the net proceeds from the sale of our shares in this offering could effectively have a material adverse effect on our business, delay the development of our products, compromise our ability to pursue our business strategy, and c

View Full Filing

View this S-1/A filing on SEC EDGAR